Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA

a technology of interalpha-inhibitor and plasma, which is applied in the field of plasma production, can solve the problems of limited commercially available blood products, inability to increase the supply of these products, and inability to manufacture new plasma raw, etc., and achieve the effect of promoting epithelial repair

Active Publication Date: 2012-03-01
TAKEDA PHARMA CO LTD
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, the supply of these products cannot be increased by simply increasing the volume of production.
Rather the level of commercially available blood products is limited by the available supply of blood and plasma donations.
This dynamic results in a shortage in the availability of raw human plasma for the manufacture of new plasma-derived blood factors that have lesser established commercial markets, including Inter-alpha-Inhibitor proteins (IaIp), such as Inter-alpha-Inhibitor (IaI) and Pre-alpha-Inhibitor (PaI), and Factor H.
This requirement will limit the availability of plasma for the manufacture of new plasma-derived blood products.
Due to the lack of plasma available for the manufacture of new plasma-derived products, their manufacture must be integrated into the existing framework of the established manufacturing processes for plasma-derived products such as immunoglobulins and albumin.
(the disclosures of which are hereby incorporated by reference in their entireties for all purposes) consume valuable starting material, will require new regulatory approvals for the established products, and / or may even result in alterations of the characteristics of the established products.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA
  • MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA
  • MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0430]To determine an economically beneficial scheme for the manufacture of Inter-alpha-Inhibitor (IaIp) from a plasma sample, which allows for the recovery of additional blood factors from the same plasma sample, a lot of pooled human plasma was subjected to industrial fractionation according to the scheme outlined in the flow-diagram shown in FIG. 2. The fate of IaIp in the industrial fractionation process was followed by Western blot using an antibody specific for the small subunit, bikunin. Due to the size difference between IaI and PaI, the anti-bikunin antibody allowed for the identification of both proteins in the fractionation process, which were distinguished based on their migration on the SDS-PAGE gel (FIG. 3).

[0431]As seen in FIG. 3, a majority of the IaIp present in the pooled plasma sample was fractionated into three major fractions, the Fraction I precipitate, the Fraction II+III precipitate filter cake, and the Fraction IV-1 precipitate. Advantageously, all three of ...

example 2

[0432]The present example describes experiments performed to determine the feasibility of extracting IaIp from a Fraction II+III filter cake. Briefly, the Fraction II+III filter cake from the plasma fractionation performed in Example 1 was dissolved in an IaIp extraction buffer (25 mM Tris (pH 8.0); 5 mM EDTA; 200 mM NaCl) at a ratio of 25:1 (mL buffer:g filtercake). The dissolved protein solution was clarified by centrifugation and filtration through a 0.45 μm filter. The conductivity of the resulting suspension was then adjusted by diluting the solution 3:1 with low salt extraction buffer (25 mM Tris (pH 8.0); 5 mM EDTA).

[0433]The clarified Fraction II+III filter cake suspension was then loaded onto a DEAE-Sepharose chromatograph column equilibrated with a low salt buffer (25 mM Tris; 5 mM EDTA; 50 mM NaCl; pH 8.0). A linear gradient from 50 mM NaCl to 500 mM NaCl (25 mM Tris; 5 mM EDTA; NaCl; pH 8.0) was then used to elute the IaIp from the DEAE-Sepharose column, the eluate of wh...

example 3

[0435]In order to aid with the industrial scale-up for the IaIp purification after extraction, an alternate purification scheme was devised that replaces the salt gradient elution of the chromatography columns with a series of step elutions that are more amenable to a large scale manufacturing process. Briefly, an IaIp composition extracted from a Fraction II+III filter cake, as described in Example 2, was loaded onto a DEAE-Sepharose chromatography column equilibrated with a low salt buffer (25 mM Tris; 5 mM EDTA; 65 mM NaCl; pH 8.0). The conductivity of the load was similar to that of the equilibration buffer (about 9 mS / cm). After the load, the column was washed with buffer containing 65 mM NaCl for 5 column volumes (CV) to remove the unbound protein impurities. The flow-through fractions contain very little IaIp as shown by the Western blot results in FIG. 7C.

[0436]In a first step elution, the salt concentration of the buffer (25 mM Tris (pH 8.0); 5 mM EDTA; NaCl) was increased ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.

Description

CROSS REFERENCES TO APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application Ser. No. 61 / 367,331, filed Jul. 23, 2010, the disclosure of which is hereby incorporated herein by reference in its entirety for all purposes.BACKGROUND OF THE INVENTION[0002]Unlike other biologics that are produced via recombinant expression of DNA vectors in host cell lines, plasma-derived proteins are fractionated from human blood and plasma donations. Thus, the supply of these products cannot be increased by simply increasing the volume of production. Rather the level of commercially available blood products is limited by the available supply of blood and plasma donations. This dynamic results in a shortage in the availability of raw human plasma for the manufacture of new plasma-derived blood factors that have lesser established commercial markets, including Inter-alpha-Inhibitor proteins (IaIp), such as Inter-alpha-Inhibitor (IaI) and Pre-alpha-Inhibitor (PaI), and Fac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/57A61P29/00A61P35/04A61P31/04A61P7/00A61P3/10A61P9/00A61P43/00C07K1/36A61P13/12
CPCC07K14/47C07K14/811
Inventor BAIRSTOW, SHAWN F.HUTSELL, JENNIFERRAMACHANDRAN, SINDHU
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com